NASDAQ:CPIX - Cumberland Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.19
▲ +0.07 (3.30%)

This chart shows the closing price for CPIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cumberland Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CPIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CPIX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cumberland Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $2.19.

This chart shows the closing price for CPIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Cumberland Pharmaceuticals. This rating has held steady since February 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2021B. RileyReiterated RatingBuyLow
3/19/2020B. RileyReiterated RatingBuyLow
12/3/2019B. RileyBoost Price TargetBuy$9.00 ➝ $9.75Medium
8/17/2018B. RileyLower Price TargetBuy ➝ Buy$9.25 ➝ $8.75Medium
4/17/2018B. RileyInitiated CoverageBuy$9.25High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 30 positive mentions
  • 10 negative mentions
  • 6 very negative mentions
10/28/2021
  • 2 very positive mentions
  • 28 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
11/27/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/27/2021
  • 3 very positive mentions
  • 15 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
1/26/2022
  • 3 very positive mentions
  • 24 positive mentions
  • 4 negative mentions
  • 10 very negative mentions
2/25/2022
  • 1 very positive mentions
  • 25 positive mentions
  • 10 negative mentions
  • 5 very negative mentions
3/27/2022
  • 3 very positive mentions
  • 29 positive mentions
  • 8 negative mentions
  • 9 very negative mentions
4/26/2022
  • 4 very positive mentions
  • 28 positive mentions
  • 4 negative mentions
  • 5 very negative mentions
5/26/2022

Current Sentiment

  • 4 very positive mentions
  • 28 positive mentions
  • 4 negative mentions
  • 5 very negative mentions

Recent Stories by Sentiment

Cumberland Pharmaceuticals logo
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Read More

Today's Range

Now: $2.19
Low: $2.12
High: $2.19

50 Day Range

MA: $2.55
Low: $2.12
High: $3.03

52 Week Range

Now: $2.19
Low: $2.12
High: $7.51

Volume

6,388 shs

Average Volume

81,475 shs

Market Capitalization

$32.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Cumberland Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Cumberland Pharmaceuticals in the last year: StockNews.com, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CPIX.

What is the current price target for Cumberland Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Cumberland Pharmaceuticals in the last year.
View the latest price targets for CPIX.

What is the current consensus analyst rating for Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CPIX.

How do I contact Cumberland Pharmaceuticals' investor relations team?

Cumberland Pharmaceuticals' physical mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company's listed phone number is (615) 255-0068 and its investor relations email address is [email protected] The official website for Cumberland Pharmaceuticals is www.cumberlandpharma.com. Learn More about contacing Cumberland Pharmaceuticals investor relations.